Researchers at Radboud University Medical Center and Maastricht University presented early implementation results at the European Society of Human Genetics meeting showing that long-read genome sequencing as a first-tier test can improve interpretation and reduce follow-up testing. The comparison evaluated the first six months of clinical long-read sequencing against prior-year short-read results. The team reported comparable diagnostic yield with long-read testing, while emphasizing improved workflow consolidation and a reduced need for additional testing to resolve ambiguous variants. They also noted expanding clinical coverage for indications that were initially selected based on predicted workflow simplification. For clinical genetics programs, the operational signal is notable: as sequencing costs and instrument capacity increase, long-read platforms may become less of an add-on and more of a default first-line diagnostic in selected indications.